Mable utilizes a genomics-based telehealth platform to analyze patients' genetic and biomarker data, creating personalized treatment plans for migraine management. This approach addresses the inefficiencies of traditional trial-and-error medication methods, aiming to enhance treatment effectiveness and reduce the frequency and intensity of migraine episodes.
Funding
Funding not disclosed
Founders
Product
Problem
Migraine sufferers often face unpredictable symptoms and inconsistent responses to traditional trial-and-error medication methods. This can lead to prolonged periods of discomfort and reduced quality of life as patients navigate various treatments without a clear understanding of their individual biological responses.
Solution
Mable offers a genomics-based telehealth platform that analyzes patients' genetic and biomarker data to create personalized migraine treatment plans. By integrating telemedicine with genomic insights, Mable aims to provide more effective and targeted care, reducing the frequency and intensity of migraine episodes. The platform offers an entirely virtual experience, from initial online consultations to DNA testing services and ongoing telehealth support. Mable's approach represents a shift toward precision medicine, tailoring treatments to each patient's unique genetic and biological characteristics, potentially improving outcomes and reducing unnecessary medication side effects.
Target Audience
Mable's primary customers are individuals seeking personalized and effective migraine management solutions through advanced genomic analysis and telehealth services.
Features
- Online consultations for initial assessment of medical history and migraine symptoms
- DNA testing services to gain insights into a patient's genetic makeup
- Analysis of genetic markers and biomarkers to provide precision medicine options
- Personalized treatment plans tailored to individual biological profiles
- Ongoing telehealth support to adjust treatments based on patient progress
- Preventive care aimed at reducing the frequency and intensity of future migraines